Noncoding RNA Gene Linked to Malignant Melanoma
|
By LabMedica International staff writers Posted on 05 Apr 2016 |

Image: Histopathology of a skin section from a patient with superficial spreading malignant melanoma (Photo courtesy of Profs. Leszek Wozniak and Krzysztof W. Zielinski).
While a large share of the human genome has long been considered “junk DNA” because it does not contribute to protein coding, recent insights indicate that it does produce many noncoding ribonucleic acids (RNAs) that play important roles in essential biological processes and diseases.
A remarkable link has been found between malignant melanoma and a noncoding RNA gene called SAMMSON. The SAMMSON gene is expressed in human malignant melanoma and, strikingly, the growth of aggressive skin cancer is highly dependent on this gene. The conclusions could pave the way for improved diagnostic tools and skin cancer treatment.
A European group of scientists led by those at the VIB, the Flanders Institute for Biotechnology (Leuven, Belgium) have shown that show that the recently annotated long noncoding RNA (lncRNA) gene SAMMSON is consistently co-gained with Microphthalmia-Associated Transcription Factor (MITF) gene. Their results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.
The scientists discovered a remarkable dependency of melanoma cells on SAMMSON expression. When reducing the presence of SAMMSON in melanoma cultures, cancer cells rapidly and massively die off, irrespective of the type of melanoma. This led to the key conclusion of a “SAMMSON addiction.” As the SAMSSON gene is not expressed in benign melanoma, its occurrence could be a key factor in developing new diagnostic tools that may dramatically improve melanoma prognosis.
Pieter Mestdagh, PhD, from Ghent University (Belgium) and a senior coauthor of the study, said, “Our study showed that the long noncoding RNA gene SAMMSON is specifically expressed in human melanomas and duplicated or amplified in about 10% of the cases. In addition, SAMMSON was nowhere to be found in melanocytes, the normal melanin-producing cells, nor in any other normal adult tissue. This unique expression profile of SAMMSON led us to hypothesize that this gene might play an important role in the etiology of melanoma.” The study was published on March 23, 2016, in the journal Nature.
Related Links:
VIB the Flanders Institute for Biotechnology
Ghent University
A remarkable link has been found between malignant melanoma and a noncoding RNA gene called SAMMSON. The SAMMSON gene is expressed in human malignant melanoma and, strikingly, the growth of aggressive skin cancer is highly dependent on this gene. The conclusions could pave the way for improved diagnostic tools and skin cancer treatment.
A European group of scientists led by those at the VIB, the Flanders Institute for Biotechnology (Leuven, Belgium) have shown that show that the recently annotated long noncoding RNA (lncRNA) gene SAMMSON is consistently co-gained with Microphthalmia-Associated Transcription Factor (MITF) gene. Their results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.
The scientists discovered a remarkable dependency of melanoma cells on SAMMSON expression. When reducing the presence of SAMMSON in melanoma cultures, cancer cells rapidly and massively die off, irrespective of the type of melanoma. This led to the key conclusion of a “SAMMSON addiction.” As the SAMSSON gene is not expressed in benign melanoma, its occurrence could be a key factor in developing new diagnostic tools that may dramatically improve melanoma prognosis.
Pieter Mestdagh, PhD, from Ghent University (Belgium) and a senior coauthor of the study, said, “Our study showed that the long noncoding RNA gene SAMMSON is specifically expressed in human melanomas and duplicated or amplified in about 10% of the cases. In addition, SAMMSON was nowhere to be found in melanocytes, the normal melanin-producing cells, nor in any other normal adult tissue. This unique expression profile of SAMMSON led us to hypothesize that this gene might play an important role in the etiology of melanoma.” The study was published on March 23, 2016, in the journal Nature.
Related Links:
VIB the Flanders Institute for Biotechnology
Ghent University
Latest Molecular Diagnostics News
- New Respiratory Panel Expands Pathogen Detection to 25 Targets
- Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
- Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
- Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
- Blood Test Helps Guide Treatment in Older Women with Breast Cancer
- Rapid Host-Response Test Distinguishes Bacterial and Viral Infections in Minutes
- Liquid Biopsy Method Pinpoints Disease Source From a Single Drop of Blood
- Study Reveals Widespread Errors in Gene Variant Naming
- New Blood Test Aims to Transform Liver Cancer Surveillance
- New Biomarkers Indicate Higher Liver Cancer Risk in Chronic Hepatitis B Patients
- Precision Analyzer Reveals ‘Chameleon Proteins’ Causing Intractable Diseases
- Alzheimer's Blood Marker Could Improve Detection of Heart and Kidney Diseases
- Single Blood Test Predicts Heart Diseases 15 Years Before Onset
- Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug
- Clinical Diagnostic Test Detects Additional Genetic Variants in Acute Leukemia Patients
- Blood Test Predicts Dementia in Women 25 Years Before Symptoms Begin
Channels
Clinical Chemistry
view channel
Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, with more than 60% of cases still diagnosed at a late stage. Uptake of existing screening tools remains suboptimal,... Read more
Automated NfL Assay Supports Monitoring of Neurological Disorders
Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. Blood-based measurement of neurofilament light chain (NfL) provides a biologically... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








